reported that the combined use of TIGIT antibody and PD-L1 antibody at the same time is far better than blocking TIGIT or PD1/PD-L1 pathway alone, which can more significantly reduce the tumor volume and the survival time of tumor-bearing mice (5). This evidence concerns the gene PDCD1 and neoplasm.